Celgene Intl Company Profile
✉ Email this page to a colleague
What is the competitive landscape for CELGENE INTL, and when can generic versions of CELGENE INTL drugs launch?
CELGENE INTL has one approved drug.
There are four US patents protecting CELGENE INTL drugs.
There are one hundred and nineteen patent family members on CELGENE INTL drugs in thirty countries and twenty-three supplementary protection certificates in thirteen countries.
Summary for Celgene Intl
| International Patents: | 119 |
| US Patents: | 4 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Celgene Intl
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-001 | Mar 25, 2020 | RX | Yes | No | 8,796,318 | See Plans and Pricing | Y | Y | See Plans and Pricing | ||
| Celgene Intl | ZEPOSIA | ozanimod hydrochloride | CAPSULE;ORAL | 209899-003 | Mar 25, 2020 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | |||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Celgene Intl Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| China | 102762100 | See Plans and Pricing |
| Slovenia | 2291080 | See Plans and Pricing |
| Canada | 2986521 | See Plans and Pricing |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Celgene Intl Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2291080 | 20C1047 | France | See Plans and Pricing | PRODUCT NAME: OZANIMOD OU SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER CHLORHYDRATE D'OZANIMOD; REGISTRATION NO/DATE: EU/1/20/1442 20200525 |
| 2291080 | PA2020529 | Lithuania | See Plans and Pricing | PRODUCT NAME: OZANIMODAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA, YPAC OZANIMODO HIDROCHLORIDAS; REGISTRATION NO/DATE: EU/1/20/1442 20200520 |
| 2291080 | 2090039-5 | Sweden | See Plans and Pricing | PRODUCT NAME: OZANIMOD OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR OZANIMOD HYDROCHLORIDE; REG. NO/DATE: EU/1/20/1442 20200525 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
